HRP20200659T1 - Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze - Google Patents
Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze Download PDFInfo
- Publication number
- HRP20200659T1 HRP20200659T1 HRP20200659TT HRP20200659T HRP20200659T1 HR P20200659 T1 HRP20200659 T1 HR P20200659T1 HR P20200659T T HRP20200659T T HR P20200659TT HR P20200659 T HRP20200659 T HR P20200659T HR P20200659 T1 HRP20200659 T1 HR P20200659T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- tipifarnib
- method includes
- administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 8
- 229950009158 tipifarnib Drugs 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 238000000018 DNA microarray Methods 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 101150117869 Hras gene Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 229940075628 hypomethylating agent Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000009120 supportive therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Claims (14)
1. Spoj, naznačen time, da se upotrebljava u postupku liječenja pločastog karcinoma glave i vrata (HNSCC) kod pacijenta, naznačen time, da pacijent ima mutaciju H-Ras, pri čemu mutacija H-Ras rezultira aktiviranjem H-Ras proteina, pri čemu je spoj tipifarnib i gdje je navedeni HNSCC metastatski, rekurentni ili refraktorni.
2. Spoj za uporabu prema zahtjevu 1, naznačen time, da mutacija H-Ras navedenog pacijenta sadrži aminokiselinu supstitucije kodona izabranog iz skupine koja se sastoji od G12, G13 i Q61.
3. Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time, da postupak uključuje utvrđivanje prisutnosti HRas mutacije u uzorku navedenog pacijenta.
4. Spoj za uporabu prema zahtjevu 3, naznačen time, da navedeni uzorak je biopsija tkiva ili biopsija tumora.
5. Spoj za uporabu u skladu s patentnim zahtjevom 3 ili 4, naznačen time što je spomenuta H-Ras mutacija određena odabranom metodom iz skupine koja se sastoji od sekvenciranja, lančana reakcija polimeraze (PCR), mikrorašćenje DNA, masena spektrometrija (MS), jednostrani nukleotidni polimorfizam (SNP), denaturiranje visoko-djelotvorne tekućinske kromatografije (DHPLC), i test polimorfizma dužine ograničenja (RFLP).
6. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što metoda uključuje primjenu tipifarniba u dozi od 1-1000 mg / kg tjelesne težine.
7. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time da postupak uključuje primjenu tipifarniba dva puta dnevno.
8. Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time što metoda uključuje primjenu tipifarniba u dozi od 600 mg dva puta dnevno ili u dozi od 900 mg dva puta dnevno.
9. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što metoda uključuje primjenu tipifarniba u trajanju od jednog do sedam dana.
10. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time što metoda uključuje primjenu tipifarniba u danima 1-7 i 15-21 od 28-dnevnog ciklusa liječenja.
11. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što metoda uključuje primjenu tipifarniba za najmanje 3 ciklusa ili najmanje 6 ciklusa.
12. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što metoda uključuje primjenu tipifarniba prije, za vrijeme ili nakon zračenja.
13. Spoj za uporabu prema bilo kojem od zahtjeva 1 do 12, naznačen time da postupak nadalje uključuje primjenu terapeutski učinkovitu količinu drugog aktivnog sredstva ili potpornu terapiju.
14. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je drugo aktivno sredstvo izabrano iz skupine koja se sastoji kemoterapeutskog sredstva, DNA-hipometilirajućeg sredstva, terapeutskog antitijela koje se specifično veže na antigen raka, hematopoetski faktor rasta, citokin, antibiotik, inhibitor cox-2, imunomodulatorni agens, antimocitni globulin, imunosupresivno sredstvo i kortikosteroid ili farmakološki derivat ili gdje je drugo aktivno sredstvo anti-PD1 antitijelo ili anti-PDL1 antitijelo.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206194P | 2015-08-17 | 2015-08-17 | |
US201562218927P | 2015-09-15 | 2015-09-15 | |
US201562241019P | 2015-10-13 | 2015-10-13 | |
US201662310582P | 2016-03-18 | 2016-03-18 | |
US201662372662P | 2016-08-09 | 2016-08-09 | |
EP18173134.0A EP3385395B9 (en) | 2015-08-17 | 2016-08-16 | Methods of treating cancer patients with farnesyl transferase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200659T1 true HRP20200659T1 (hr) | 2020-08-07 |
Family
ID=56802700
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211976TT HRP20211976T1 (hr) | 2015-08-17 | 2016-08-16 | Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze |
HRP20191424TT HRP20191424T2 (hr) | 2015-08-17 | 2019-08-07 | Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze |
HRP20200659TT HRP20200659T1 (hr) | 2015-08-17 | 2020-04-23 | Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211976TT HRP20211976T1 (hr) | 2015-08-17 | 2016-08-16 | Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze |
HRP20191424TT HRP20191424T2 (hr) | 2015-08-17 | 2019-08-07 | Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze |
Country Status (29)
Country | Link |
---|---|
US (7) | US10471055B2 (hr) |
EP (4) | EP3640345B9 (hr) |
JP (4) | JP6630742B2 (hr) |
KR (4) | KR20210048600A (hr) |
CN (5) | CN114107497A (hr) |
AU (3) | AU2016308564B2 (hr) |
BR (1) | BR112018003091A2 (hr) |
CA (1) | CA2985123C (hr) |
CY (3) | CY1122037T1 (hr) |
DK (3) | DK3277842T5 (hr) |
EA (1) | EA201890512A1 (hr) |
ES (3) | ES2901506T3 (hr) |
HK (1) | HK1254087A1 (hr) |
HR (3) | HRP20211976T1 (hr) |
HU (3) | HUE044698T2 (hr) |
IL (1) | IL257547B (hr) |
LT (3) | LT3385395T (hr) |
MX (1) | MX2018001769A (hr) |
MY (1) | MY195484A (hr) |
NZ (1) | NZ736853A (hr) |
PH (1) | PH12018500322A1 (hr) |
PL (3) | PL3277842T3 (hr) |
PT (3) | PT3277842T (hr) |
RS (3) | RS59158B9 (hr) |
SG (1) | SG10202101740QA (hr) |
SI (3) | SI3385395T1 (hr) |
TW (3) | TWI621437B (hr) |
WO (1) | WO2017031101A1 (hr) |
ZA (2) | ZA201801047B (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3277842T5 (da) * | 2015-08-17 | 2020-08-31 | Kura Oncology Inc | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer |
US11124839B2 (en) * | 2016-11-03 | 2021-09-21 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
BR112020002591A2 (pt) | 2017-08-07 | 2020-07-28 | Kura Oncology, Inc. | método para o tratamento de câncer |
WO2019113269A1 (en) * | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
EP3873469A2 (en) * | 2018-11-01 | 2021-09-08 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
EP3897638A1 (en) * | 2018-12-21 | 2021-10-27 | Kura Oncology, Inc. | Therapies for squamous cell carcinomas |
CN110656172A (zh) * | 2019-01-14 | 2020-01-07 | 南方医科大学珠江医院 | 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒 |
TW202108170A (zh) * | 2019-03-15 | 2021-03-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法 |
WO2020198144A1 (en) * | 2019-03-22 | 2020-10-01 | The Regents Of The University Of California | Chmp2a as a regulator of natural killer cell-mediated activity |
JP2022527495A (ja) * | 2019-03-29 | 2022-06-02 | クラ オンコロジー, インコーポレイテッド | ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法 |
CN110241461A (zh) * | 2019-06-24 | 2019-09-17 | 厦门大学 | 一种构建人nk细胞免疫球蛋白样受体文库的多重pcr引物和方法 |
CN111097039B (zh) * | 2020-01-16 | 2020-11-06 | 南京医科大学 | Ras相关蛋白2的制药用途 |
CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
EP4146346A1 (en) * | 2020-05-08 | 2023-03-15 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
CN111863126B (zh) * | 2020-05-28 | 2024-03-26 | 上海市生物医药技术研究院 | 构建结直肠肿瘤状态评估模型的方法及应用 |
US20240058321A1 (en) * | 2021-11-02 | 2024-02-22 | Semmelweis Egyetem | Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers |
CN114045339B (zh) * | 2021-11-05 | 2022-06-28 | 山东第一医科大学附属省立医院(山东省立医院) | 铁死亡相关基因在弥漫大b细胞淋巴瘤预后评估中的应用 |
WO2023242097A1 (en) * | 2022-06-13 | 2023-12-21 | KHR Biotec GmbH | Mitoxanthrone derivatives as ras inhibitors |
WO2023242104A1 (en) * | 2022-06-13 | 2023-12-21 | KHR Biotec GmbH | Diaminoacridine derivatives as inhibitors of ras |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5420245A (en) | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
US5976851A (en) | 1990-04-18 | 1999-11-02 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification, characterization, and inhibition of farnesyl protein transferase |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5702885A (en) | 1990-06-27 | 1997-12-30 | The Blood Center Research Foundation, Inc. | Method for HLA typing |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
ZA918965B (en) | 1990-11-13 | 1992-08-26 | Siska Diagnostics Inc | Nucleic acid amplification by two-enzyme,self-sustained sequence replication |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5238922A (en) | 1991-09-30 | 1993-08-24 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
ATE205542T1 (de) | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5504212A (en) | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
EP0698015A1 (en) | 1993-05-14 | 1996-02-28 | Genentech, Inc. | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
US5965539A (en) | 1993-05-18 | 1999-10-12 | Univeristy Of Pittsburgh | Inhibitors of prenyl transferases |
US5602098A (en) | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
FR2721021B1 (fr) | 1994-06-10 | 1996-07-12 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent. |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5491164A (en) | 1994-09-29 | 1996-02-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
FR2729390A1 (fr) | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2730491B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5578629A (en) | 1995-03-29 | 1996-11-26 | Merck & Co., Inc. | Benzamide-containing inhibitors of farnesyl-protein transferase |
US5534537A (en) | 1995-03-29 | 1996-07-09 | Merck & Co., Inc. | Prodrugs of inhibitors of farnesyl-protein transferase |
US5972984A (en) | 1995-06-06 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
FR2736641B1 (fr) | 1995-07-10 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2736638B1 (fr) | 1995-07-12 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
CA2231105C (en) | 1995-12-08 | 2005-09-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5859015A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | N-heterocyclic piperazinyl and H-heterocyclic piperazinonyl inhibitors of farnesyl-protein transferase |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5780492A (en) | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5965578A (en) | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000508661A (ja) | 1996-04-15 | 2000-07-11 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 放射線および化学療法に対する細胞の感作 |
US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5767274A (en) | 1996-06-28 | 1998-06-16 | Biomeasure, Incorporated | Prenyl transferase inhibitors |
US5773455A (en) | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
KR100232231B1 (ko) | 1996-09-13 | 2000-03-02 | 김영환 | 비휘발성 메모리 소자의 데이터 기입 장치 및 방법 |
US5777324A (en) | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6024925A (en) | 1997-01-23 | 2000-02-15 | Sequenom, Inc. | Systems and methods for preparing low volume analyte array elements |
US5972966A (en) | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
JP2001505548A (ja) | 1996-12-20 | 2001-04-24 | トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” | 凍結乾燥ハイドロクロライド−1β,10β−エポキシ−13−ジメチルアミノ−グアヤ−3(4)−エン−6,12−オリドの生成方法および装置 |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
AU738628B2 (en) * | 1997-04-25 | 2001-09-20 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
CA2290992C (en) | 1997-06-02 | 2008-02-12 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
HUP0100221A3 (en) | 1998-01-16 | 2002-11-28 | Takeda Pharmaceutical | Sustained release compositions, process for producing the same and utilization thereof |
DE69902012T2 (de) | 1998-03-05 | 2002-11-21 | Formula One Administration Ltd | Datenübertragungssystem |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6104028A (en) | 1998-05-29 | 2000-08-15 | Genetrace Systems Inc. | Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
CA2337800C (en) | 1998-07-06 | 2007-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating arthropathies |
TR200003879T2 (tr) | 1998-07-06 | 2007-01-22 | Janssen Pharmaceutica N.V. | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ |
WO2000012498A1 (en) | 1998-08-27 | 2000-03-09 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
JP3495706B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
ATE240327T1 (de) | 1998-12-23 | 2003-05-15 | Janssen Pharmaceutica Nv | 1,2-annelierte chinolinderivate |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20040157882A1 (en) | 1999-11-30 | 2004-08-12 | End David William | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
AU3074001A (en) | 1999-12-09 | 2001-06-18 | Advanced Research And Technology Institute, Inc. | Fluorescent in situ rt-pcr |
US6670124B1 (en) | 1999-12-20 | 2003-12-30 | Stemcyte, Inc. | High throughput methods of HLA typing |
ES2262626T3 (es) | 2000-02-04 | 2006-12-01 | Janssen Pharmaceutica N.V. | Inhibidores de farnesil proteina transferasa para tratar cancer de mama. |
DE60130976T2 (de) | 2000-02-24 | 2008-07-17 | Janssen Pharmaceutica N.V. | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
WO2002043733A1 (en) | 2000-11-28 | 2002-06-06 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
EP1365763B1 (en) | 2001-02-15 | 2008-11-26 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
PT3351246T (pt) * | 2001-02-19 | 2019-06-07 | Novartis Pharma Ag | Derivado de rapamicina para o tratamento de um tumor sólido associado a angiogenese desregulada |
JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Pcr法 |
JP4257698B2 (ja) | 2001-03-12 | 2009-04-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物の製造方法 |
EP1390033A1 (en) | 2001-04-25 | 2004-02-25 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating cachexia |
CN101426928A (zh) * | 2001-10-30 | 2009-05-06 | 奥索临床诊断有限公司 | 评价和治疗白血病的方法 |
JP2005522990A (ja) | 2001-10-30 | 2005-08-04 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | 白血病の評価及び処理方法 |
EP1490065B1 (en) | 2002-03-22 | 2007-06-13 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20080280289A1 (en) | 2003-10-22 | 2008-11-13 | Pel-Freez Clinical Systems, Inc. | Primers, Methods and Kits for Detecting Killer-Cell Immunoglobulin-Like Receptor Alleles |
EP1536021A1 (en) | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
CN100567291C (zh) | 2004-05-03 | 2009-12-09 | 詹森药业有限公司 | 用6-溴-4-(3-氯苯基)-2-甲氧基喹啉进行的非对映选择性合成方法 |
JP4917021B2 (ja) | 2004-05-03 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | スルフィンイミン類に対するリチオ化されたn−メチルイミダゾールのジアステレオ選択的付加 |
CA2563807C (en) | 2004-05-03 | 2012-11-20 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
EP1815247B1 (en) | 2004-11-05 | 2013-02-20 | Janssen Pharmaceutica NV | Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof |
US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
WO2007041067A2 (en) | 2005-09-29 | 2007-04-12 | Children's Hospital & Research Center At Oakland | Methods and compositions for kir genotyping |
ATE475408T1 (de) | 2005-10-14 | 2010-08-15 | Janssen Pharmaceutica Nv | Formulierungen von tipifarnib zur intravenösen verabreichung |
WO2009051672A2 (en) | 2007-10-12 | 2009-04-23 | St. Jude Children's Research Hospital | Natural killer immunoglobulin-like receptor (kir) assay |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
EP2307041B1 (en) | 2008-06-03 | 2019-03-13 | Janssen Pharmaceutica, N.V. | Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment |
US8771951B2 (en) | 2009-11-16 | 2014-07-08 | Genomics Usa, Inc. | Methods for PCR and HLA typing using raw blood |
US11559540B2 (en) | 2010-07-28 | 2023-01-24 | Janssen Pharmaceutica Nv | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
EP2598874B1 (en) * | 2010-07-28 | 2018-10-24 | Janssen Diagnostics, LLC | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
WO2012047985A1 (en) | 2010-10-06 | 2012-04-12 | St. Jude Children's Research Hospital | Molecular determinant-based typing of kir alleles and kir-ligands |
NZ711948A (en) * | 2013-03-13 | 2020-02-28 | Oncoceutics Inc | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
WO2015144184A1 (en) | 2014-03-26 | 2015-10-01 | University Of Copenhagen | Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer |
EP3134436A4 (en) * | 2014-04-25 | 2017-12-27 | Memorial Sloan Kettering Cancer Center | Treatment of h-ras-driven tumors |
DK3277842T5 (da) | 2015-08-17 | 2020-08-31 | Kura Oncology Inc | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer |
US11124839B2 (en) * | 2016-11-03 | 2021-09-21 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
-
2016
- 2016-08-16 DK DK16757791.5T patent/DK3277842T5/da active
- 2016-08-16 KR KR1020217012290A patent/KR20210048600A/ko not_active Application Discontinuation
- 2016-08-16 LT LTEP18173134.0T patent/LT3385395T/lt unknown
- 2016-08-16 PT PT16757791T patent/PT3277842T/pt unknown
- 2016-08-16 EP EP19210527.8A patent/EP3640345B9/en active Active
- 2016-08-16 KR KR1020177033442A patent/KR101885361B1/ko active IP Right Grant
- 2016-08-16 HU HUE16757791 patent/HUE044698T2/hu unknown
- 2016-08-16 EP EP21200474.1A patent/EP3995589A1/en not_active Withdrawn
- 2016-08-16 EA EA201890512A patent/EA201890512A1/ru unknown
- 2016-08-16 RS RS20191040A patent/RS59158B9/sr unknown
- 2016-08-16 KR KR1020187020999A patent/KR102125496B1/ko active IP Right Grant
- 2016-08-16 SI SI201630721T patent/SI3385395T1/sl unknown
- 2016-08-16 CN CN202111313741.1A patent/CN114107497A/zh active Pending
- 2016-08-16 KR KR1020207017328A patent/KR102246710B1/ko active IP Right Grant
- 2016-08-16 MY MYPI2018700584A patent/MY195484A/en unknown
- 2016-08-16 CN CN201810463246.0A patent/CN108371711A/zh active Pending
- 2016-08-16 TW TW105126133A patent/TWI621437B/zh active
- 2016-08-16 SI SI201630340T patent/SI3277842T1/sl unknown
- 2016-08-16 DK DK19210527.8T patent/DK3640345T3/da active
- 2016-08-16 HU HUE18173134A patent/HUE049620T2/hu unknown
- 2016-08-16 PL PL16757791T patent/PL3277842T3/pl unknown
- 2016-08-16 SG SG10202101740QA patent/SG10202101740QA/en unknown
- 2016-08-16 EP EP18173134.0A patent/EP3385395B9/en active Active
- 2016-08-16 AU AU2016308564A patent/AU2016308564B2/en active Active
- 2016-08-16 HU HUE19210527A patent/HUE057306T2/hu unknown
- 2016-08-16 PL PL19210527T patent/PL3640345T3/pl unknown
- 2016-08-16 CN CN202010013228.XA patent/CN111214658B/zh active Active
- 2016-08-16 TW TW107101407A patent/TWI710642B/zh active
- 2016-08-16 PT PT192105278T patent/PT3640345T/pt unknown
- 2016-08-16 SI SI201631418T patent/SI3640345T1/sl unknown
- 2016-08-16 NZ NZ73685316A patent/NZ736853A/en unknown
- 2016-08-16 CN CN201680031764.4A patent/CN107787373B/zh active Active
- 2016-08-16 PL PL18173134T patent/PL3385395T3/pl unknown
- 2016-08-16 US US15/238,458 patent/US10471055B2/en active Active
- 2016-08-16 TW TW109136957A patent/TW202129012A/zh unknown
- 2016-08-16 LT LT16757791T patent/LT3277842T/lt unknown
- 2016-08-16 PT PT181731340T patent/PT3385395T/pt unknown
- 2016-08-16 JP JP2017558498A patent/JP6630742B2/ja active Active
- 2016-08-16 RS RS20211538A patent/RS62709B1/sr unknown
- 2016-08-16 ES ES19210527T patent/ES2901506T3/es active Active
- 2016-08-16 MX MX2018001769A patent/MX2018001769A/es unknown
- 2016-08-16 EP EP16757791.5A patent/EP3277842B9/en active Active
- 2016-08-16 ES ES16757791T patent/ES2741782T3/es active Active
- 2016-08-16 CA CA2985123A patent/CA2985123C/en active Active
- 2016-08-16 HR HRP20211976TT patent/HRP20211976T1/hr unknown
- 2016-08-16 BR BR112018003091-0A patent/BR112018003091A2/pt active IP Right Grant
- 2016-08-16 DK DK18173134.0T patent/DK3385395T3/da active
- 2016-08-16 ES ES18173134T patent/ES2787073T3/es active Active
- 2016-08-16 WO PCT/US2016/047140 patent/WO2017031101A1/en active Application Filing
- 2016-08-16 LT LTEP19210527.8T patent/LT3640345T/lt unknown
- 2016-08-16 RS RS20200412A patent/RS60149B9/sr unknown
- 2016-08-16 CN CN202111299593.2A patent/CN114306604A/zh active Pending
- 2016-11-08 US US15/346,675 patent/US9707221B2/en active Active
-
2017
- 2017-07-06 US US15/643,387 patent/US10022364B2/en active Active
- 2017-12-15 US US15/844,478 patent/US10335404B2/en active Active
-
2018
- 2018-02-13 PH PH12018500322A patent/PH12018500322A1/en unknown
- 2018-02-15 IL IL257547A patent/IL257547B/en unknown
- 2018-02-15 ZA ZA2018/01047A patent/ZA201801047B/en unknown
- 2018-02-26 US US15/905,711 patent/US10292979B2/en active Active
- 2018-05-02 AU AU2018203045A patent/AU2018203045C1/en active Active
- 2018-06-13 US US16/007,931 patent/US11207314B2/en active Active
- 2018-10-15 HK HK18113151.8A patent/HK1254087A1/zh unknown
-
2019
- 2019-02-11 ZA ZA2019/00858A patent/ZA201900858B/en unknown
- 2019-08-07 HR HRP20191424TT patent/HRP20191424T2/hr unknown
- 2019-09-06 JP JP2019162505A patent/JP7323393B2/ja active Active
- 2019-09-16 CY CY20191100966T patent/CY1122037T1/el unknown
-
2020
- 2020-04-23 HR HRP20200659TT patent/HRP20200659T1/hr unknown
- 2020-04-27 CY CY20201100379T patent/CY1123067T1/el unknown
- 2020-12-04 AU AU2020281160A patent/AU2020281160B2/en active Active
-
2021
- 2021-12-23 CY CY20211101131T patent/CY1124879T1/el unknown
-
2022
- 2022-01-20 JP JP2022007005A patent/JP2022058680A/ja active Pending
- 2022-05-31 US US17/829,183 patent/US20230089412A1/en active Pending
-
2023
- 2023-12-13 JP JP2023209791A patent/JP2024037857A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200659T1 (hr) | Metode liječenja pacijenata oboljelih od raka pomoću inhibitora farnezil transferaze | |
JP2020002164A5 (hr) | ||
Liu et al. | HDAC11: a rising star in epigenetics | |
JP2024037857A5 (hr) | ||
Lange et al. | AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro | |
HRP20161108T1 (hr) | Bezstanična dnk kao terapeutsko ciljno mjesto za neplodnost kod jedinki ženskog spola i dijagnostički marker | |
JP2019194190A5 (hr) | ||
BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
US11946889B2 (en) | Differential scanning microcalorimeter device for detecting disease and monitoring therapeutic efficacy | |
HRP20170613T1 (hr) | Antikoagulacijski protuotrovi | |
TW201427664A (zh) | Tec家族激酶抑制劑佐劑療法 | |
JP2016520520A5 (hr) | ||
US20140363425A1 (en) | Systems and methods for identifying cancers having activated progesterone receptors | |
JP2018515493A5 (hr) | ||
JP2016520289A5 (hr) | ||
JP2019534298A5 (hr) | ||
Germano et al. | Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines | |
JP2012523376A5 (hr) | ||
Kuroda et al. | All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase | |
JP2022527412A (ja) | がんの治療にセネカバレーウイルス(svv)を使用する組成物および方法 | |
Nagasaka et al. | Lysine-specific demethylase 1 (LSD1/KDM1A) is a novel target gene of c-Myc | |
RU2016135933A (ru) | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству | |
Pizzi et al. | Inhibition of IκBα phosphorylation prevents glutamate-induced NF-κB activation and neuronal cell death | |
EP4049282A1 (en) | Methods and compositions for high-throughput compressed screening for therapeutics | |
Adams et al. | A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen‐activated protein kinase pathway to activate c‐Jun N‐terminal kinase and a functional AP‐1 containing c‐Jun and c‐Fos proteins in mouse NB2a cells |